There is currently great interest in developing improved methods of immunotherapy and new techniques of immune system manipulation to ameliorate allergic diseases. This article reviews current research trends in the immunologic treatment of allergy, including the use of chemically modified allergens, nonparenteral allergen exposure, sustained-release allergen delivery, anti-immunoglobulin E antibodies, γ-globulin, immune complexes, cytokines, and T-cell-tolerogenic peptides.
Get full access to this article
View all access options for this article.
References
1.
CurtisHHThe immunizing cure of hay fever. Med New1900; 77:16–8.
2.
FranklandAWAugustinR.Prophylaxis of summer hayfever and asthma. A controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet1954; 1:1055–8.
3.
LowellFCFranklinW.A double blind study of the effectiveness and specificity of injection therapy in ragweed hay fever. N Engl J Med1965; 273:675–9.
4.
JohnstoneDEDuttonA.The value of hyposensitization therapy for bronchial asthma in children—a 14 year study. Pediatrics1968; 42:793–802.
5.
HedlinGGraff-LonnevigVHellbornHImmunotherapy with cat- and dog-dander extracts. J Allergy Clin Immunol1991; 87:955–64.
6.
HuntKJValentineMDSobotkaAKA controlled trial of immunotherapy in insect sensitivity. JAMA1978; 299:157–61.
LockeyRFBenedictLMTurkeltaubPCFatalities from immunotherapy and skin testing. J Allergy Clin Immunol1987; 79:660–77.
9.
ChapmanMDUse of nonstimulatory peptides: A new strategy for immunotherapy?J Allergy Clin Immunol1991; 88: 300–2.
10.
NakagawaTGershwinMEImmunotherapy of allergic diseases. Int Arch Allergy Immunol1993; 102:117–20.
11.
TaudorfE.Oral immunotherapy of adults with allergic rhinoconjunctivitis: Clinical effects in birch and grass pollinosis. Danish Med Bull1992; 39:542–60.
12.
NelsonHSOppenheimerJVatsiaGAA double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol1993; 92:229–36.
13.
Saint-RemyJ-MR.Novel approaches in immunotherapy. Clin Rev Allergy1994; 12:23–42.
14.
DreborgSAkerblomEBImmunotherapy with monomethoxypolyethylene glycol modified allergens. Crit Rev Ther Drug Carrier Syst1990; 6:315–65.
15.
SehonAHSuppression of antibody responses by chemically modified antigens. Int Arch Allergy Appl Immunol1991:94: 11–20.
16.
TakagiINishimuraJItohHPoly(lactic/glycolic acid) microspheres containing antigen as a novel and potential agent of immunotherapy for allergic disorders. Jpn J Allergol1992; 41:1388–97.
17.
WallsAFLiposomes for allergy immunotherapy?Clin Exp Allergy1992; 22:1–2.
18.
HellmanL.Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur J Immunol1994; 24:415–20.
19.
SchusterAWahnV.Intravenous Verabreichte Immunoglobuline bei Asthma Bronchiale: Eine Therapeutische Alternative?Infusionsther Transfusionsmed1993; 20(suppl 1):140–5.
20.
PowrieFCoffmanRLCytokine regulation of T-cell function: Potential for therapeutic intervention. Trends Pharmacol Sci1993; 14:164–8.
21.
HoltPGA potential vaccine strategy for asthma and allied atopic diseases during early childhood. Lancet1994; 344: 456–8.
22.
MarshallGDCytokines: Clinical potentials for the allergic patient. Allergy Proc1992; 13:311–5.
23.
MohaptraSSModulation of allergen-specific antibody responses by T-cell-based peptide vaccines: Principles and potential. Clin Rev Allergy1994; 12:3–21.
24.
JarmanERHawrylowiczCMPanagiotopolouEInhibition of human T-cell responses to house dust mite allergens by a T-cell receptor peptide. J Allergy Clin Immunol1994; 94:844–52.
25.
WallnerBPGefterMLImmunotherapy with T-cell-reactive peptides derived from allergens. Allergy1994; 49:302–8.
